英文名稱 | Mobocertinib (TAK-788) |
---|---|
中文名稱 | 莫博替尼 |
CAS號(hào) | 1847461-43-1 |
分子式 | C32H39N7O4 |
分子量 | 585.70 |
外觀 | Off-white to light yellow powder |
儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專享價(jià) | 數(shù)量 |
---|---|---|---|---|
25 mg | 3-5days | ¥650.00 | 登錄后可見(jiàn) | |
50 mg | 3-5days | ¥910.00 | 登錄后可見(jiàn) | |
100 mg | 3-5days | ¥1276.00 | 登錄后可見(jiàn) |
英文名稱 | Mobocertinib (TAK-788) |
---|---|
中文名稱 | 莫博替尼 |
CAS號(hào) | 1847461-43-1 |
分子式 | C32H39N7O4 |
分子量 | 585.70 |
外觀 | Off-white to light yellow powder |
儲(chǔ)存條件 | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Mobocertinib (TAK-788; AP-32788; Exkivity), a drug used for the treatment of non-small cell lung cancer (NSCLC), is a novel, highly potent, irreversible and orally bioavailable inhibitor of EGFR and HER2 oncogenic mutants (e.g. exon 20 insertions), and exhibits high selectivity over WT EGFR.